Seeking Alpha

Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate...

Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate Pimavanserin worked very well reducing hallucinations and delusions related to Parkinson's Disease during Phase III testing.
Comments (1)
  • This is extremely positive news for Acadia for eventually approval of Pimavanserin. Those of us who have significant stock in the company have enjoyed a substantial increase in value since it introduction in the market. I anticipate a multi million world wide market for this drug which offers relief to those suffering from the neurological effects of Parkinson disease .
    21 Mar 2013, 05:38 PM Reply Like
DJIA (DIA) S&P 500 (SPY)